Clinical trials: Cardiotoxicity, open to volunteers
Cardiotoxicity, Heart Failure
Novel On-body Evaluation of Cardiac Health for Oncology
The goal of this study is to develop a wearable sensor system that can estimate left ventricular ejection fraction (LVEF), which is a measurement of the heart's function.
- Trial name
- NOECHO (NCT07158450)
- Where
- 11 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Skribe Medical
Sarcoma,Soft Tissue
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic.
- Trial name
- NCT07874828
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy.
- Trial name
- RAGE (NCT05256745)
- Testing
- TTP488, ddAC/ddT, TC
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Georgetown University
Cardiotoxicity
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
- Trial name
- NCT07663357
- Where
- 6 sites in Brazil
- Volunteers
- 1,000 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Breast Cancer, Hematologic Malignancy
Global Cardio Oncology Registry
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and…
- Conditions
- Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity
- Trial name
- G-COR (NCT05598879)
- Testing
- anonymized data collection during programmed surveillance clinical follow up
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- The Cleveland Clinic
Cancer and / or Hematological Malignancy, Anthracycline-induced Cardiotoxicity
BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry
The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across…
- Trial name
- BHF-COLLATE (NCT07864467)
- Where
- 6 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health.
- Conditions
- Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
- Trial name
- NCT07426913
- Testing
- Cardiovascular Health Education and Gaming through Virtual Reality
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Chronic Lymphocytic Leukemia, Atrial Fibrillation
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms.
- Conditions
- Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
- Trial name
- SENTINEL (NCT06211413)
- Testing
- no intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
- Trial name
- NCT06491680
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Helwan University
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Solid Tumor
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study
The purpose of the present study is to evaluate cardiotoxicity during re-challenge of a different modality of fluoropyrimidine (primary end-point S-1 and secondary any other fluoropyrimidine) after having perceived cardiotoxicity…
- Trial name
- CardioSwitch (NCT04260269)
- Testing
- Fluoropyrimidine
- Where
- 13 sites in Denmark, Finland and 5 more
- Volunteers
- 200 people
- Sponsor
- Helsinki University Central Hospital
Multiple Myeloma
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
Multiple myeloma (MM) is a malignant proliferative plasma cell disease, which accounts for approximately 10% and ranks secondly of hematological malignancies in many countries.
- Trial name
- NCT06039735
- Testing
- Chemotherapy and/or autologous hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Hospital of Shandong University
Cardiotoxicity
Artificial Intelligence for Reconstruction of Echocardiography Studies
To investigate the clinical utility of both 3D and 2D artificial intelligence reconstruction echocardiography (V-echo and L-echo) assessment against conventional echocardiography and clinical cardiovascular magnetic resonance…
- Trial name
- AIRES (NCT07093918)
- Testing
- V-echo, L-echo
- Volunteers
- 120 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Heart Failure, Cardiotoxicity
The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial
Pediatric, adolescent and young adult cancer survivors (PAYA-CS) are at higher risk of cardiovascular (CV) morbidity and mortality.
- Conditions
- Heart Failure, Cardiotoxicity, Cancer
- Trial name
- HIMALAYAS (NCT05023785)
- Testing
- Cardio-oncology Rehabilitation (CORE)
- Where
- Canada
- Volunteers
- 336 people
- Sponsor
- University Health Network, Toronto
Immune Checkpoint Inhibitors, Cardiotoxicity
Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity
This study is a prospective cohort clinical research that analyzes the changes in CMR parameters before and after immune checkpoint inhibitors (ICIs) therapy in patients with gynecologic malignancies.
- Trial name
- NCT06132984
- Testing
- Cardiac magnetic resonance
- Where
- China
- Volunteers
- 22 people
- Sponsor
- West China Second University Hospital
Locally Advanced Lung Non-Small Cell Carcinoma
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)
The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy.
- Trial name
- LM (NCT06361784)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer, Cardiotoxicity
A Study of Blood Pressure Control During Cancer Treatment
The purpose of this study to find out whether an intensive approach to treating high blood pressure during breast cancer treatment is safe and more effective than standard blood pressure treatment at lowering blood pressure…
- Trial name
- NCT06023576
- Testing
- antihypertensive medications, Blood pressure measurement, Echocardiogram
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
The CARDIOPROTECT Trial
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care…
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Trial name
- NCT07654426
- Testing
- Dexrazoxane, Doxorubicin, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cardiotoxicity
Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age
To test whether the implementation of new diagnostic techniques (ultrasonography, speckle tracking, vascular stiffness study, cardiac MRI, and histologic studies) allows in CAYA (Childern, Adolescents, and Young Adults) cancer…
- Trial name
- PREDICT (NCT07382141)
- Testing
- Parameters of vascular stiffness
- Where
- 5 sites in Italy
- Volunteers
- 400 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Car T- Cell, Hematologic Malignancy
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
CAR-T cells (Chimeric Antigen Receptor) are a new immunotherapy, based on the genetic modification of autologous T lymphocytes. CAR-T cell therapy is not devoid of complications.
- Conditions
- Car T- Cell, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Lymphoma, B-Cell
- Trial name
- Cardio CAR-T (NCT06350994)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris